Vertex Pharmaceuticals · 2 weeks ago
Vertex Summer 2026 Intern, Process Chemistry
Vertex Pharmaceuticals is a global biotechnology company focused on tackling serious diseases and changing lives. They are seeking a Process Chemistry Intern to gain hands-on experience in Drug Substance Development, applying synthetic organic chemistry principles in the development of processes for Active Pharmaceutical Ingredients.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Work closely with an experienced process chemist to learn the fundamental knowledge and laboratory techniques on process development and optimization, synthesis and characterization of small molecule organic compounds, developing analytical thinking and problem-solving skills
Maintains a well-written and organized notebook
Involves in group discussion, present work and communicate with other team members
Qualification
Required
Must be pursuing a Bachelor's degree in chemistry
Undergraduate student with completion of a minimum of one year of university studies
Completed college coursework for General Chemistry and Organic Chemistry and associated laboratory work
Excellent communication, collaboration and interpersonal skills
Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization
You must be enrolled in an advanced degree program if graduating before August 2026
You must be available to work full-time, 40 hours per week from May – August 2026
Benefits
Free 24/7 onsite gym access and free access to group exercise classes
Subsidized commuter benefits- transit and parking
Provided meals—free breakfast daily!
Career development opportunities and events, including C Suite engagement
Social events—both intern-only and company-wide
Location-specific perks and extras!
Recognition of National Intern Day
Company
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$657.31MKey Investors
Janssen Belgium
2024-07-10Post Ipo Secondary· $1.11M
2022-05-17Post Ipo Equity· $50M
2009-12-03Post Ipo Equity· $443M
Leadership Team
Recent News
2026-01-05
Company data provided by crunchbase